Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera
Results from the phase 3 VERIFY trial of rusfertide for erythrocytosis in patients with polycythemia vera led to the FDA decision.
Previous Post
Clinical and Educational Advantages of Simulations in Training the Next Generation of Neurologists: Nuri Jacoby, MD
Next Post
HHS terminates NIH program aimed at diversifying biomedical workforce
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago